title: [Incidence of adverse drug reactions in patients initiating or changing antiretroviral therapy].
abstract: BACKGROUND
  In the Chilean AIDS Cohort, the 15.9% of the patients change the first scheme of HAART because of toxicity, which is also the cause of 47% suspensions of treatment occurred in the first months of therapy.
  
  
  OBJECTIVE
  To analyze the incidence and causality of adverse drug reactions in patients initiating or changing antiretroviral therapy.
  
  
  METHODS
  92 patients who started or changed antiretroviral treatment in a period from May to July 2011 were followed to detect adverse drug reactions.
  
  
  RESULTS
  75% (n: 69) of patients had at least one adverse event. From a total of 76 adverse drug reactions detected the most frequent ones were diarrhea (21.1%, n: 16) and hyperbilirubinemia (19.7% n: 15). 85.9% of the adverse events where grade depending on its seriousness, 34.1% had grade 1 toxicity, 32.9% grade 2, 9.4% grade 3 and only 3.5% grade 4. Only 22 patients (31.8%) required a treatment change. The most frequent causes for changing treatment were because of anaemia by AZT (45.4%, n: 10) and diarrhea associated with the use of LPV/r (27.3%, n: 6).
  
  
  CONCLUSIONS
  Knowing the real incidence rate of adverse drug reactions may help the health team giving proper management and monitoring of these reactions in the patient, in order to avoid an early change of HAART. Defining a multidisciplinary team which includes a pharmacist is essential for proper pharmacosurveillance.
authors.affiliation: Policlínico de Infectología, Hospital San Juan de Dios, Santiago, Chile.
authors.forename: Fernando
authors.initials: F
authors.lastname: Bernal
authors.forename: Patricia
authors.initials: P
authors.lastname: Vásquez
authors.forename: Carolina
authors.initials: C
authors.lastname: Giadalah
authors.forename: Lorena
authors.initials: L
authors.lastname: Rodríguez
authors.forename: Alejandra
authors.initials: A
authors.lastname: Villagrán
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002677:Chile / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged
chemical_list: D019380:Anti-HIV Agents